{"title":"AHR suppresses cisplatin-induced apoptosis in ovarian cancer cells by regulating XIAP","authors":"Geng Shen , Surong Xu , Anqi Zhu , Zhipeng Zheng , Wei Chen , Songshan Jiang","doi":"10.1016/j.bcp.2024.116640","DOIUrl":null,"url":null,"abstract":"<div><div>X-linked inhibitor of apoptosis protein (XIAP) plays a crucial role in cisplatin-induced apoptosis in ovarian cancer, whereas the molecular mechanism of how its expression is dysregulated remains unclear. Here, we report that the aryl hydrocarbon receptor (AHR) acts as a competitive endogenous RNA (ceRNA) of XIAP and can regulate its expression. Overexpression of AHR 3′UTR decreased, while AHR knockdown increased, the cisplatin-induced apoptotic rate in ovarian cancer cells. We also found that one microRNA (miRNA), miR-142-5p, can bind to both AHR and XIAP 3′UTRs and regulate their expression levels. Furthermore, AHR 3′UTR and miR-142-5p can occupy the same Ago2 to form an RNA-induced silencing complex (RISC). In addition, we showed that the effect of AHR overexpression on cisplatin-induced apoptosis could be rescued by either XIAP siRNA or miR-142-5p mimic. Thus, our findings reveal important insights into the molecular mechanism underlying the dysregulation of XIAP in ovarian cancer, indicating that AHR serves as the ceRNA that competes miR-142-5p with XIAP and subsequently affects the platinum-based chemotherapy.</div></div>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":"231 ","pages":"Article 116640"},"PeriodicalIF":5.3000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0006295224006403","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
X-linked inhibitor of apoptosis protein (XIAP) plays a crucial role in cisplatin-induced apoptosis in ovarian cancer, whereas the molecular mechanism of how its expression is dysregulated remains unclear. Here, we report that the aryl hydrocarbon receptor (AHR) acts as a competitive endogenous RNA (ceRNA) of XIAP and can regulate its expression. Overexpression of AHR 3′UTR decreased, while AHR knockdown increased, the cisplatin-induced apoptotic rate in ovarian cancer cells. We also found that one microRNA (miRNA), miR-142-5p, can bind to both AHR and XIAP 3′UTRs and regulate their expression levels. Furthermore, AHR 3′UTR and miR-142-5p can occupy the same Ago2 to form an RNA-induced silencing complex (RISC). In addition, we showed that the effect of AHR overexpression on cisplatin-induced apoptosis could be rescued by either XIAP siRNA or miR-142-5p mimic. Thus, our findings reveal important insights into the molecular mechanism underlying the dysregulation of XIAP in ovarian cancer, indicating that AHR serves as the ceRNA that competes miR-142-5p with XIAP and subsequently affects the platinum-based chemotherapy.
期刊介绍:
Biochemical Pharmacology publishes original research findings, Commentaries and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics.
The journal''s target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process.
All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complimentary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review.
While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy.